Switching to Faricimab or High‐Dose Aflibercept for Neovascular AMD in High‐Demand Patients: Impact on Injection Interval in a Real‐World Cohort

Documenti analoghi

• Intravitreal Ranibizumab Injections Significantly Influence Retinal Venous Calibre in Patients With Diabetic Macular Oedema
  di: Luke K. Chehade, et al.
  Pubblicazione: (2025)
• Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia
  di: Mark Gillies, et al.
  Pubblicazione: (2026)
• Elevated aqueous TNF‐α levels are associated with more severe functional and anatomic findings in eyes with diabetic macular oedema
  di: Sky Chew, et al.
  Pubblicazione: (2024)
• Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry
  di: Adrian Hunt, et al.
  Pubblicazione: (2025)
• Reducing the Carbon Footprint of Neovascular Age–Related Macular Degeneration Therapy: Environmental Impact of Transitioning to Aflibercept 8 mg
  di: Daniele Veritti, et al.
  Pubblicazione: (2026)